Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.5452 | 1 | 0.5 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0927 | 0.1048 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0683 | 0.0565 | 0.5392 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.5452 | 1 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.5452 | 1 | 0.5 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0815 | 0.0827 | 1 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0739 | 0.0675 | 0.8166 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.5452 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1004 | 0.1199 | 1 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.1004 | 0.1199 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.5452 | 1 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.5452 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.5452 | 1 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.1004 | 0.1199 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.